Statistical monitoring services in response to ICH GCP E6(R2) addendum reduce time and resource23 Nov 2017
Offers customers a comprehensive, risk-based approach to the monitoring of data quality throughout the course of a study.
Quanticate has launched its centralised statistical monitoring service as an extension of its statistical consultancy offering in response to recent amendments to the International Conference of Harmonisation (ICH) Good Clinical Practice (GCP) E6(R2) guidelines.
The new service will offer Quanticate’s customers statistical consultancy that incorporates a risk-based approach into clinical trials. As well as introducing measures to evaluate risk into protocol design and statistical analysis plans, the company will also be able to determine the degree of monitoring required by conducting statistical tests guided by a risk-based approach. This will in turn help to guide decisions surrounding investigations into data discrepancies and identifying where site-directed monitoring visits may be necessary.
The GCP guidelines are aimed at setting a quality standard when designing, conducting, recording and reporting on trials in humans. The recent ICH GCP E6(R2) addendum advises that incorporating risk-based monitoring approaches into clinical trial design could help companies to ensure the safety and quality of clinical trials by identifying and mitigating risks, as well as ensuring that any incorrect data is identified, in the early stages.
Dr Daniel Chapple, director at Quanticate said: “These new guidelines demonstrate that the industry is recognising the importance of driving down the cost of drug development and in the long run reducing the cost of medicines for patients.
“Risk-based monitoring is becoming more popular as it is recognised as a cost-effective and efficient method of data analysis. Centralising statistical monitoring, as opposed to on-site source data verification, can make risk-based monitoring easier as it reduces the need to visit all clinical trial sites for data analysis and verification as it can be outsourced to one supplier, reducing time and resource.
“Optimising trials by reducing monitoring visits should be welcomed by the pharmaceutical industry and the ICH GCP E6(R2) addendum will help to drive companies towards streamlining clinical trials in this way.
Quanticate’s decision to introduce its new centralised statistical monitoring service has been driven by the niche CROs commitment to streamlining clinical data management and analysis for its customers.
Alan Morgan, Chief Operating Officer, said: “Statistics play a key role in analysing and making decisions on study data and Quanticate’s new service offering puts us in an ideal place to support pharmaceutical and biotechnology companies as they opt to centrally monitor their data and introduce risk-based approaches into their study designs.
“There is a clear sponsor benefit to using an independent company to perform statistical monitoring and validate the work of the organisation driving site and patient recruitment through regular review of study data.
“As a company that specialises in statistics, Quanticate offers customers a comprehensive, risk-based approach to the monitoring of data quality throughout the course of a study.”
Quanticate will be launching the new service at the annual Partnerships in Clinical Trials 2017 conference in Amsterdam between 28th-29th November 2017. Visit stand 19.
BIA Separations expands with new upstream processing facility
20 Sep 2018
Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.Read more
Sanofi to refocus two global business units
19 Sep 2018
The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.Read more
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years
18 Sep 2018
China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.Read more
Recipharm connects to European Hub for serialisation compliance
18 Sep 2018
Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.Read more
Bosch to unveil new laboratory device for continuous manufacturing
18 Sep 2018
The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.Read more
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions
17 Sep 2018
Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.Read more
Cambrex expands manufacturing footprint with acquisition
16 Sep 2018
Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.Read more
NMPA approves fruquintinib capsules for metastatic colorectal cancer
13 Sep 2018
Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.Read more
Aptar Pharma to showcase an industry first
12 Sep 2018
PureHale is a new portable drug delivery device designed for upper respiratory care.Read more
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio
11 Sep 2018
The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation